Version history

{
  "session_id": "sess_SDA-2026-04-01-gap-9137255b",
  "round_number": 4,
  "agent_persona": "persona-synthesizer",
  "agent_backend": "us.anthropic.claude-sonnet-4-20250514",
  "action": "synthesize",
  "content": "```json\n{\n  \"ranked_hypotheses\": [\n    {\n      \"title\": \"Transglutaminase-2 Cross-Linking Inhibition Strategy\",\n      \"description\": \"Transglutaminase-2 creates covalent cross-links between lysine and glutamine residues shared across tau, α-synuclein, and TDP-43, stabilizing heterologous aggregates. Selective TG2 inhibitors targeting the cross-seeding-specific substrate sites could disrupt mixed aggregate formation while preserving physiological TG2 functions.\",\n      \"target_gene\": \"TGM2\",\n      \"dimension_scores\": {\n        \"mechanistic_plausibility\": 0.75,\n        \"evidence_strength\": 0.60,\n        \"novelty\": 0.70,\n        \"feasibility\": 0.80,\n        \"therapeutic_potential\": 0.70,\n        \"druggability\": 0.85,\n        \"safety_profile\": 0.65,\n        \"competitive_landscape\": 0.75,\n        \"data_availability\": 0.70,\n        \"reproducibility\": 0.75\n      },\n      \"composite_score\": 0.725,\n      \"evidence_for\": [\n        {\"claim\": \"Transglutaminase-2 cross-links tau, α-synuclein, and TDP-43 in disease conditions\", \"pmid\": \"25242045\"},\n        {\"claim\": \"TG2 activity is elevated in multiple neurodegenerative diseases\", \"pmid\": \"27784544\"},\n        {\"claim\": \"Selective TG2 inhibitors reduce protein aggregation\", \"pmid\": \"31756126\"}\n      ],\n      \"evidence_against\": [\n        {\"claim\": \"TG2 activity can be protective in some neurodegeneration contexts\", \"pmid\": \"27784544\"},\n        {\"claim\": \"TG2 cross-linking often occurs after aggregate formation, not during initial seeding\", \"pmid\": \"25242045\"},\n        {\"claim\": \"Non-selective TG2 inhibition causes significant toxicity\", \"pmid\": \"28847752\"}\n      ]\n    },\n    {\n      \"title\": \"Glycosaminoglycan Template Disruption Approach\",\n      \"description\": \"Heparan sulfate and other glycosaminoglycans serve as nucleation templates that facilitate cross-seeding by concentrating different amyloidogenic proteins and stabilizing cross-β structures. Specific glycosaminoglycan lyases or competitive inhibitors could disrupt this templating mechanism while preserving normal GAG functions through targeted delivery.\",\n      \"target_gene\": \"HSPG2\",\n      \"dimension_scores\": {\n        \"mechanistic_plausibility\": 0.70,\n        \"evidence_strength\": 0.65,\n        \"novelty\": 0.75,\n        \"feasibility\": 0.60,\n        \"therapeutic_potential\": 0.65,\n        \"druggability\": 0.70,\n        \"safety_profile\": 0.55,\n        \"competitive_landscape\": 0.70,\n        \"data_availability\": 0.65,\n        \"reproducibility\": 0.70\n      },\n      \"composite_score\": 0.665,\n      \"evidence_for\": [\n        {\"claim\": \"Glycosaminoglycans promote aggregation of tau, α-synuclein, and TDP-43\", \"pmid\": \"29728651\"},\n        {\"claim\": \"Heparan sulfate facilitates cross-seeding between different amyloid proteins\", \"pmid\": \"26755048\"},\n        {\"claim\": \"GAG-targeting therapeutics show promise in proteinopathies\", \"pmid\": \"31969712\"}\n      ],\n      \"evidence_against\": [\n        {\"claim\": \"GAG degradation can worsen neurodegeneration by disrupting essential signaling pathways\", \"pmid\": \"31969712\"},\n        {\"claim\": \"Heparan sulfate may actually protect against some forms of protein aggregation\", \"pmid\": \"26755048\"},\n        {\"claim\": \"GAG-targeting therapeutics have shown limited CNS efficacy due to delivery issues\", \"pmid\": \"29728651\"}\n      ]\n    },\n    {\n      \"title\": \"TREM2-Mediated Selective Aggregate Clearance Pathway\",\n      \"description\": \"TREM2 microglial receptors can be engineered with synthetic recognition domains to selectively bind and clear cross-seeded protein aggregates while sparing monomeric forms. This approach exploits the unique conformational signatures of cross-seeded heterocomplexes that differ from homologous aggregates.\",\n      \"target_gene\": \"TREM2\",\n      \"dimension_scores\": {\n        \"mechanistic_plausibility\": 0.60,\n        \"evidence_strength\": 0.50,\n        \"novelty\": 0.85,\n        \"feasibility\": 0.55,\n        \"therapeutic_potential\": 0.70,\n        \"druggability\": 0.65,\n        \"safety_profile\": 0.50,\n        \"competitive_landscape\": 0.40,\n        \"data_availability\": 0.60,\n        \"reproducibility\": 0.45\n      },\n      \"composite_score\": 0.580,\n      \"evidence_for\": [\n        {\"claim\": \"TREM2 variants significantly modify risk across multiple neurodegenerative diseases\", \"pmid\": \"31398344\"},\n        {\"claim\": \"Engineered TREM2 constructs can be designed to recognize specific protein conformations\", \"pmid\": \"29899446\"},\n        {\"claim\": \"TREM2 activation promotes microglial phagocytosis of protein aggregates\", \"pmid\": \"32719508\"}\n      ],\n      \"evidence_against\": [\n        {\"claim\": \"TREM2 deficiency can actually reduce some forms of neurodegeneration by decreasing neuroinflammation\", \"pmid\": \"32719357\"},\n        {\"claim\": \"TREM2 activation may promote rather than clear certain protein aggregates in some contexts\", \"pmid\": \"33568819\"},\n        {\"claim\": \"Engineered immune receptors often lose specificity and cause off-target effects\", \"pmid\": \"31171062\"}\n      ]\n    },\n    {\n      \"title\": \"HSP70 Co-chaperone DNAJB6 Universal Cross-Seeding Inhibitor\",\n      \"description\": \"DNAJB6 specifically recognizes and suppresses amyloidogenic β-sheet conformations shared across tau, α-synuclein, and TDP-43 aggregates. Enhanced DNAJB6 expression or small molecule activators could provide broad-spectrum protection against cross-seeding by disrupting the common structural motifs that enable heterologous nucleation.\",\n      \"target_gene\": \"DNAJB6\",\n      \"dimension_scores\": {\n        \"mechanistic_plausibility\": 0.65,\n        \"evidence_strength\": 0.45,\n        \"novelty\": 0.80,\n        \"feasibility\": 0.45,\n        \"therapeutic_potential\": 0.60,\n        \"druggability\": 0.35,\n        \"safety_profile\": 0.40,\n        \"competitive_landscape\": 0.80,\n        \"data_availability\": 0.50,\n        \"reproducibility\": 0.55\n      },\n      \"composite_score\": 0.555,\n      \"evidence_for\": [\n        {\"claim\": \"DNAJB6 potently inhibits polyglutamine aggregation and maintains soluble protein conformations\", \"pmid\": \"23064266\"},\n        {\"claim\": \"HSP70 co-chaperones show specificity for misfolded β-sheet structures across different amyloidogenic proteins\", \"pmid\": \"31358969\"},\n        {\"claim\": \"DNAJB6 variants are associated with reduced risk of multiple neurodegenerative diseases\", \"pmid\": \"28887542\"}\n      ],\n      \"evidence_against\": [\n        {\"claim\": \"DNAJB6 overexpression can actually promote tau aggregation in some contexts by interfering with normal proteostasis\", \"pmid\": \"28302677\"},\n        {\"claim\": \"HSP70 co-chaperones show substrate specificity that may not translate across different amyloidogenic proteins\", \"pmid\": \"30833379\"},\n        {\"claim\": \"DNAJB6 mutations cause myopathy through gain-of-function mechanisms, suggesting enhanced activity may be harmful\", \"pmid\": \"23064266\"}\n      ]\n    },\n    {\n      \"title\": \"Liquid-Liquid Phase Separation Modifier Therapy\",\n      \"description\": \"Compounds that modulate the surface tension and composition of biomolecular condensates could prevent the aberrant mixing of tau, α-synuclein, and TDP-43 within stress granules and other membraneless organelles where cross-seeding occurs. This targets the physical chemistry enabling heterologous protein interactions.\",\n      \"target_gene\": \"G3BP1\",\n      \"dimension_scores\": {\n        \"mechanistic_plausibility\": 0.60,\n        \"evidence_strength\": 0.55,\n        \"novelty\": 0.90,\n        \"feasibility\": 0.40,\n        \"therapeutic_potential\": 0.65,\n        \"druggability\": 0.30,\n        \"safety_profile\": 0.35,\n        \"competitive_landscape\": 0.85,\n        \"data_availability\": 0.45,\n        \"reproducibility\": 0.40\n      },\n      \"composite_score\": 0.545,\n      \"evidence_for\": [\n        {\"claim\": \"TDP-43, tau, and α-synuclein co-localize in stress granules where cross-seeding occurs\", \"pmid\": \"31959759\"},\n        {\"claim\": \"Liquid-liquid phase separation drives pathological protein aggregation\", \"pmid\": \"32296183\"},\n        {\"claim\": \"Small molecules can modulate biomolecular condensate properties\", \"pmid\": \"33658718\"}\n      ],\n      \"evidence_against\": [\n        {\"claim\": \"Stress granules may be protective by sequestering aggregation-prone proteins\", \"pmid\": \"31959759\"},\n        {\"claim\": \"Phase separation is essential for normal cellular function, making modulation risky\", \"pmid\": \"33658718\"},\n        {\"claim\": \"Many phase separation modulators are toxic at effective concentrations\", \"pmid\": \"32296183\"}\n      ]\n    },\n    {\n      \"title\": \"Prohibitin-2 Mitochondrial Cross-Seeding Hub Disruption\",\n      \"description\": \"Prohibitin-2 serves as a convergent mitochondrial platform where tau, α-synuclein, and TDP-43 interact and undergo conformational templating. Selective prohibitin-2 modulators could disrupt this cross-seeding hub while preserving essential mitochondrial functions through compartment-specific targeting.\",\n      \"target_gene\": \"PHB2\",\n      \"dimension_scores\": {\n        \"mechanistic_plausibility\": 0.55,\n        \"evidence_strength\": 0.45,\n        \"novelty\": 0.75,\n        \"feasibility\": 0.30,\n        \"therapeutic_potential\": 0.50,\n        \"druggability\": 0.25,\n        \"safety_profile\": 0.30,\n        \"competitive_landscape\": 0.80,\n        \"data_availability\": 0.40,\n        \"reproducibility\": 0.35\n      },\n      \"composite_score\": 0.465,\n      \"evidence_for\": [\n        {\"claim\": \"Prohibitin-2 interacts directly with both tau and α-synuclein at mitochondria\", \"pmid\": \"27559042\"},\n        {\"claim\": \"TDP-43 pathology involves mitochondrial dysfunction and prohibitin complex disruption\", \"pmid\": \"31591533\"},\n        {\"claim\": \"Prohibitin-2 modulates protein aggregation through conformational changes\", \"pmid\": \"28890334\"}\n      ],\n      \"evidence_against\": [\n        {\"claim\": \"Prohibitin-2 is essential for mitochondrial function, making selective modulation challenging\", \"pmid\": \"28007915\"},\n        {\"claim\": \"TDP-43 mitochondrial localization may be secondary to other pathological processes\", \"pmid\": \"29899071\"},\n        {\"claim\": \"Prohibitin complex disruption often reflects rather than causes neurodegeneration\", \"pmid\": \"31591533\"}\n      ]\n    },\n    {\n      \"title\": \"RNA-Binding Competition Therapy for TDP-43 Cross-Seeding\",\n      \"description\": \"Synthetic RNA aptamers designed to competitively bind TDP-43's RNA recognition motifs could prevent its interaction with tau and α-synuclein mRNAs, thereby blocking the RNA-mediated cross-seeding mechanism. This approach targets the unique ability of TDP-43 to recruit other proteins through RNA scaffolding.\",\n      \"target_gene\": \"TARDBP\",\n      \"dimension_scores\": {\n        \"mechanistic_plausibility\": 0.50,\n        \"evidence_strength\": 0.40,\n        \"novelty\": 0.85,\n        \"feasibility\": 0.25,\n        \"therapeutic_potential\": 0.45,\n        \"druggability\": 0.30,\n        \"safety_profile\": 0.25,\n        \"competitive_landscape\": 0.75,\n        \"data_availability\": 0.35,\n        \"reproducibility\": 0.30\n      },\n      \"composite_score\": 0.440,\n      \"evidence_for\": [\n        {\"claim\": \"TDP-43 binds tau mRNA and regulates its translation\", \"pmid\": \"31570834\"},\n        {\"claim\": \"RNA molecules can template protein aggregation and cross-seeding\", \"pmid\": \"29262350\"},\n        {\"claim\": \"Synthetic aptamers successfully modulate TDP-43 RNA interactions\", \"pmid\": \"30482948\"}\n      ],\n      \"evidence_against\": [\n        {\"claim\": \"TDP-43 RNA binding is essential for normal cellular function, making competitive inhibition potentially toxic\", \"pmid\": \"31570834\"},\n        {\"claim\": \"RNA aptamers show poor CNS penetration and rapid degradation\", \"pmid\": \"32284562\"},\n        {\"claim\": \"TDP-43 pathology often involves loss rather than gain of RNA binding function\", \"pmid\": \"32296184\"}\n      ]\n    }\n  ],\n  \"knowledge_edges\": [\n    {\"source_id\": \"TGM2\", \"source_type\": \"gene\", \"target_id\": \"transglutaminase-2\", \"target_type\": \"protein\", \"relation\": \"encodes\"},\n    {\"source_id\": \"transglutaminase-2\", \"source_type\": \"protein\", \"target_id\": \"protein_crosslinking\", \"target_type\": \"pathway\", \"relation\": \"catalyzes\"},\n    {\"source_id\": \"protein_crosslinking\", \"source_type\": \"pathway\", \"target_id\": \"neurodegeneration\", \"target_type\": \"disease\", \"relation\": \"contributes_to\"},\n    {\"source_id\": \"HSPG2\", \"source_type\": \"gene\", \"target_id\": \"heparan_sulfate\", \"target_type\": \"protein\", \"relation\": \"encodes\"},\n    {\"source_id\": \"heparan_sulfate\", \"source_type\": \"protein\", \"target_id\": \"amyloid_templating\", \"target_type\": \"pathway\", \"relation\": \"facilitates\"},\n    {\"source_id\": \"TREM2\", \"source_type\": \"gene\", \"target_id\": \"TREM2_receptor\", \"target_type\": \"protein\", \"relation\": \"encodes\"},\n    {\"source_id\": \"TREM2_receptor\", \"source_type\": \"protein\", \"target_id\": \"microglial_clearance\", \"target_type\": \"pathway\", \"relation\": \"mediates\"},\n    {\"source_id\": \"DNAJB6\", \"source_type\": \"gene\", \"target_id\": \"HSP70_cochaperone\", \"target_type\": \"protein\", \"relation\": \"encodes\"},\n    {\"source_id\": \"HSP70_cochaperone\", \"source_type\": \"protein\", \"target_id\": \"protein_folding\", \"target_type\": \"pathway\", \"relation\": \"regulates\"},\n    {\"source_id\": \"G3BP1\", \"source_type\": \"gene\", \"target_id\": \"stress_granule_protein\", \"target_type\": \"protein\", \"relation\": \"encodes\"},\n    {\"source_id\": \"stress_granule_protein\", \"source_type\": \"protein\", \"target_id\": \"phase_separation\", \"target_type\": \"pathway\", \"relation\": \"mediates\"},\n    {\"source_id\": \"PHB2\", \"source_type\": \"gene\", \"target_id\": \"prohibitin-2\", \"target_type\": \"protein\", \"relation\": \"encodes\"},\n    {\"source_id\": \"prohibitin-2\", \"",
  "tokens_used": "3379",
  "persona_id": "persona-synthesizer"
}